NXgenPort today announced that it has entered into a license agreement with Mayo Clinic to develop and test an implantable chemo-port catheter.

NXgenPort’s technology has chemo-port efficacy with sensor technology to measure and remotely monitor the early onset of complications by reporting and tracking patient response during treatment.

“NXgenPort will bring the benefits of remote patient monitoring to cancer patients, who may have limited support between their treatments. Advances in sensor technology are enabling better patient management in diabetes and heart function care – it is time for cancer patients to benefit as well,” NXgenPort chief sciences officer Rosanne Welcher said in a news release.

The implantable chemo-port catheter uses microelectronic sensors that remotely monitor patients and report physiological body functions over the course of cancer treatment.

Under the agreement, Mayo Clinic’s center for digital health medical director and breast oncologist Tufia Haddad will advise NXgenPort.

“Support Dr. Haddad and Mayo Clinic will be invaluable in this critical stage of prototype development. So often, companies can waste money and time building products that do not fit within the workflow of clinicians or within the needs of organizations. Having early input from Dr. Haddad will help us build a product from the beginning that has value, scalability and increased potential for adoption,” NXgenPort cofounder Cathy Skinner said.